Proposed pathways include modulation of multiple neurotransmitter systems (influencing serotonin, dopamine, norepinephrine, GABA, glutamate levels), possible involvement of NMDA receptors, alpha-1 adrenergic signaling (e.g., potentiating pineal acetyltransferase activity), inhibition of somatostatin release via dopaminergic routes, reduced ACTH/cortisol for stress buffering, and stimulated growth hormone or somatoliberin secretion
In discussions around GLP 1 therapies, Huberman consistently points out that while pharmacology can drive significant fat loss, long term outcomes still depend on training, nutrition, and lifestyle structure
Take the first step towards a healthier you with us today.
[DOI] [PubMed] [Google Scholar] 300.Kim S., Islam J., Kim J., Koh Y., Hwang J., Kim H.T., Seong S.-Y